-

10:21:19 AM

CHRS Stock News

CHRS - Coherus Biosciences Inc

08/04/22 4:01 PM

Nasdaq : CHRS

Coherus BioSciences Reports Second Quarter 2022 Results and Provides Business Update

– Commercial launch of CIMERLI ™ planned for early October 2022 – – PDUFA date for toripalimab BLA is December 23, 2022 – – Commercial preparation underway for planned July 2023 launch of YUSIMRY ™ – – UDENYCA® delivers 2 nd quarter 2022 net sales of $60.1 million – – Conference call today at 5

RHEA-AI

neutral

08/02/22 7:15 PM

Nasdaq : CHRS

fda approval

FDA Approves Coherus’ CIMERLI™ (ranibizumab-eqrn) as the First and Only Interchangeable Biosimilar to Lucentis® for All Five Indications, with 12 Months of Interchangeability Exclusivity

- CIMERLI™ is Coherus’ third FDA-approved product and the first of four new product launches planned by the end of 2023 - - First CIMERLI™ product sales expected in October 2022 - - COLUMBUS AMD trial was published in the journal Ophthalmology and demonstrated the clinical equivalence of CIMERLI™

RHEA-AI

very positive

08/01/22 11:15 PM

Nasdaq : CHRS

Coherus BioSciences Announces New Employment Inducement Grants

Coherus BioSciences, Inc. (“Coherus” or the “Company”, Nasdaq: CHRS), today announced that effective August 1, 2022, the compensation committee of the Company’s board of directors granted options to purchase an aggregate of 250,000 shares of

RHEA-AI

very positive

07/28/22 4:01 PM

Nasdaq : CHRS

conferencesearnings

Coherus BioSciences to Report Second Quarter 2022 Financial Results on August 4th, 2022

Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today announced that its second quarter 2022 financial results will be released after market close on Thursday, August 4 th, 2022. Starting at 5 p.m. ET, Coherus’ management team will host

RHEA-AI

neutral

07/06/22 8:00 AM

Nasdaq : CHRS

Coherus and Junshi Biosciences Announce FDA Acceptance of Resubmission of BLA for Toripalimab for the Treatment of Nasopharyngeal Carcinoma

Coherus BioSciences, Inc. (“Coherus”,

RHEA-AI

positive

06/22/22 4:30 PM

Nasdaq : CHRS

Coherus BioSciences Announces New Employment Inducement Grants

Coherus BioSciences, Inc. (“Coherus” or the “Company”, Nasdaq: CHRS), today announced that effective June 16, 2022, the compensation committee of the Company’s board of directors granted options to purchase an aggregate of 409,000 shares of

RHEA-AI

very positive

05/11/22 6:00 PM

Nasdaq : CHRS

management

Coherus BioSciences Appoints Dr. Jill O’Donnell-Tormey to its Board of Directors

Coherus Biosciences, Inc. (“Coherus”, Nasdaq: CHRS) today announced

RHEA-AI

very positive

05/10/22 8:45 AM

Nasdaq : CHRS

conferences

Coherus BioSciences Management to Present at Upcoming Investor Conferences

Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), announced today that senior management will present at the following investor conferences in May. BofA Securities 2022 Healthcare Conference on Thursday, May 12 at 3:00 p.m. ET UBS Global

RHEA-AI

neutral

05/05/22 4:01 PM

Nasdaq : CHRS

Coherus BioSciences Reports First Quarter 2022 Results

– CIMERLI ™ BLA review progressing toward August 2022 action date – – Toripalimab BLA resubmission expected by mid-summer – – UDENYCA® delivers 1 st quarter 2022 net sales of $60.1 million – – 2022 R&D and SG&A expense guidance reduced by $20 million – – Conference call today at 4:30 p.m. ET –

RHEA-AI

positive

05/05/22 8:31 AM

Nasdaq : CHRS

management

Coherus BioSciences Appoints Charlie Newton to Board of Directors

Coherus BioSciences, Inc. (“Coherus” or the “Company”,

RHEA-AI

neutral

1 2 3 4 5 6 7 8 9 10 Next